The prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in colorectal carcinoma
Authors:
- Shai LinnSLShai Linn
- Boris FutermanBFBoris Futerman
- Ira MinkovIMIra Minkov
- Dan D. HershkoDHDan D. Hershko
Open Access
- 16 February 2005
- Vol. 103 (7) , 1336-1346
Abstract
BACKGROUND: Loss of the cell‐cycle inhibitory protein p27Kip1 is associated with poor prognosis in colorectal carcinoma. The decrease in p27Kip1 levels is the result of increased proteasome‐dependent degradation, mediated and rate‐limited by its specific ubiquitin ligase subunits S‐phase kinase protein (Skp) 2 and cyclin‐dependent kinase subunit (Cks) 1. Recently, Skp2 and Cks1 expression were found to be increased in some colorectal carcinomas, but their potential role as prognostic markers for survival is unknown. The present study was undertaken to assess the prognostic value of both Skp2 and Cks1 in colorectal carcinoma.MATERIALS AND METHODS: The expression of Skp2, Cks1, and p27Kip1 was examined by immunohistochemistry using highly specific antibodies on formalin‐fixed, paraffin‐embedded tissue sections from 80 patients with colorectal carcinoma.RESULTS: Overexpression of Skp2 and Cks1 strongly correlated with loss of p27Kip1 and loss of tumor differentiation. A significant decrease in overall survival was observed in patients expressing high Skp2 or Cks1 levels, and in particular, patients with Stage II and III disease. Each protein provided significant additional prognostic information to that given by disease stage, tumor grade, or p27Kip1 expression.CONCLUSIONS: Results suggest that overexpression of Skp2 or Cks1 is strongly associated with poor prognosis and may thus be used as prognostic markers for overall survival in colorectal carcinoma. Cancer 2005. © 2005 American Cancer Society.Keywords
This publication has 21 references indexed in Scilit:
- Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinomaCancer, 2004
- Inverse Relationship Between Skp2 Ubiquitin Ligase and the Cyclin Dependent Kinase Inhibitor p27 Kip1 in Prostate CancerJournal of Urology, 2003
- Therapeutic anti-cancer targets upstream of the proteasomeCancer Treatment Reviews, 2003
- Phase I Trial of the Proteasome Inhibitor PS-341 in Patients With Refractory Hematologic MalignanciesJournal of Clinical Oncology, 2002
- A CDK-Independent Function of Mammalian Cks1Molecular Cell, 2001
- SCF and Cullin/RING H2-Based Ubiquitin LigasesAnnual Review of Cell and Developmental Biology, 1999
- p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27Current Biology, 1999
- THE UBIQUITIN SYSTEMAnnual Review of Biochemistry, 1998
- Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancerNature Medicine, 1997
- Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27Science, 1995